Sonnet BioTherapeutics (SONN) Insider Trading & Ownership $1.42 +0.02 (+1.14%) As of 03:29 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Sonnet BioTherapeutics (NASDAQ:SONN) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.00%Number OfInsiders Buying(Last 3 Years)4Amount OfInsider Buying(Last 3 Years)$105,416.74Number OfInsiders Selling(Last 3 Years)0 Get SONN Insider Trade Alerts Want to know when executives and insiders are buying or selling Sonnet BioTherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address SONN Insider Buying and Selling by Quarter Sonnet BioTherapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/14/2023Susan DexterInsiderBuy454$15.40$6,991.60 5/30/2023Albert D DyrnessDirectorBuy1,057$10.34$10,929.38 5/17/2023Nailesh BhattDirectorBuy1,136$5.06$5,748.16 5/15/2023Pankaj MohanCEOBuy16,890$4.84$81,747.60 (Data available from 1/1/2013 forward) SONN Insider Trading Activity - Frequently Asked Questions Who is on Sonnet BioTherapeutics's Insider Roster? The list of insiders at Sonnet BioTherapeutics includes Albert D Dyrness, Nailesh Bhatt, Pankaj Mohan, and Susan Dexter. Learn more on insiders at SONN. What percentage of Sonnet BioTherapeutics stock is owned by insiders? 2.00% of Sonnet BioTherapeutics stock is owned by insiders. Learn more on SONN's insider holdings. Which Sonnet BioTherapeutics insiders have been buying company stock? The following insiders have purchased SONN shares in the last 24 months: Albert D Dyrness ($10,929.38), Nailesh Bhatt ($5,748.16), Pankaj Mohan ($81,747.60), and Susan Dexter ($6,991.60). How much insider buying is happening at Sonnet BioTherapeutics? Insiders have purchased a total of 19,537 SONN shares in the last 24 months for a total of $105,416.74 bought. Sonnet BioTherapeutics Key ExecutivesDr. Pankaj Mohan Ph.D. (Age 59)Founder, Chairman, CEO & President Compensation: $927kDr. John K. Cini Ph.D. (Age 71)Chief Scientific Officer & Co-Founder Compensation: $602.48kMr. Jay Cross (Age 53)Chief Financial Officer Compensation: $603.42kMr. Donald J. Griffith CPA (Age 75)CPA, Controller & Director Compensation: $134.05kMs. Susan Dexter (Age 69)Chief Technical Officer Dr. Richard T. Kenney FACP (Age 66)M.D., Chief Medical Officer Mr. Manuel DafonsecaHead of Clinical Operations More Insider Trading Tools from MarketBeat Related Companies UBX Insider Ownership BFRG Insider Ownership BCTX Insider Ownership BIVI Insider Ownership MIRA Insider Ownership GLYC Insider Ownership COCP Insider Ownership PHIO Insider Ownership INAB Insider Ownership CLRB Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold This page (NASDAQ:SONN) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
